Gilead Sciences, Inc. (Public, NASDAQ:GILD) reported earnings yesterday, but the blow-out-quarter doesn't seem to be impressing investors today, as shares are down 3%. Here is a summary of the call: * Net profit 72 cents/share beats 67 cents/share estimate * Revenue increases 31 pct to $1.8 billion Gilead Sciences Inc said on Tuesday its quarterly profit rose 36 percent, due in part to royalties on sales of the flu drug, Tamiflu, but sales of its core HIV drugs failed to impress investors ...

Gilead Sciences (GILD) reported financial results for the second quarter of 2009 on July 21, 2009. Total revenues increased 29% year over year to $1,647.2 million, beating our forecast by $35 million.  Revenues were driven by the company’s HIV franchise which posted sales of $1,410 million, up 26% year over year.  HIV franchise sales consisted of Viread at $159 million, Truvada at $608 million and Atripla at $569 million. Sales of Atripla, which is a combination of Truvada and Bristol-Myers Squibb’s (BMY) Sustiva, increased 60% year over year. However, there was some inventory stocking during the reported quarter.  Total product sales for the second quarter were $1,568 million, an increase of 27% year over year. Products like Hepsera ($67 million), AmBisome ($73 million), Letairis ($44 million), and Ranexa ($36 million) also contributed meaningfully to revenues. Royalties and other revenues totaled $78.8 million. ...

For Immediate Release

Chicago, IL – March 20, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Analog Devices Inc. (ADI), Gilead Sciences (GILD), CV Therapeutics (CVTX), Koninklijke Philips Electronics N.V. (PHG) and Skyworks Solutions, Inc. (SWKS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

ADI Strategy Tough for Near Term

Most of Analog Devices Inc.'s (ADI) products are in the analog category. Analog and mixed-signal products tend to be more customized, with relatively longer life cycles than digital components.

Consequently, sales of older

...

Highlights include Gilead Sciences, Inc. (GILD), Pfizer Inc. (PFE) and CV Therapeutics, Inc. (CVTX).Gilead's Outstanding Acquisition Track RecordGilead Sciences (GILD) is perhaps world's premier play on HIV/AIDS therapy. We consider Truvada -- a reformulation of drugs Viread and Emtriva -- to be a potential breakthrough product for the treatment of HIV/AIDS. Additionally, the approval of Atripla offers the next big wave of top-line growth for the company.Gilead has previously done an outstanding job in strategic acquisitions. The Triangle Pharmaceuticals deal in 2002 was the stepping stone for the basis of leading product, Truvada and Atripla.Similarly, the acquisition of Myogen, and with it Letairis and darusentan, is also looking like an excellent move. Letairis should become the "best-in-class" ETRA for PAH, and given the lack of drug-drug interactions seen in the phase III trials, it should be used ...

Gilead Sciences, Inc. (GILD) is a biotechnology company that develops and markets drugs for infectious diseases, including viral, fungal and bacterial infections. The company also has specialized focus on developing drugs for patients suffering from HIV/AIDS.We remain optimistic about growth of HIV/AIDS franchise drugs Truvada and the recently approved Atripla. Earnings over the past few quarters have been above expectations specifically on strong sales of the HIV franchise products.We continue to be positive on the name and would recommend opportunistic buying at this level. We view the name as a core biotech to own. Our target is $55.Read the full analyst report on GILD "GILD" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

Gilead Sciences, Inc.'s (...

Gilead Sciences, Inc. (GILD) is a biotechnology company that develops and markets drugs for infectious diseases, including viral, fungal and bacterial infections. The company also has specialized focus on developing drugs for patients suffering from HIV/AIDS.We remain optimistic about growth of HIV/AIDS franchise drugs Truvada and the recently approved Atripla. Earnings over the past few quarters have been above expectations, specifically on strong sales of the HIV franchise products.We continue to be positive on the name and would recommend opportunistic buying at this level. We view the name as a core biotech to own. Our target is $52.Read the full analyst report on GILD "GILD" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

Foster City, CA, based Gilead Sciences, Inc. (GILD) is perhaps the world's premier play on HIV/AIDS therapy.  Gilead's third quarter financial results were solid -- nothing new -- for the company, as management has posted upside surprise after upside surprise throughout the past several years. EPS of $0.55 in the quarter was $0.02 above our forecasts based on strong product sales and lower-than-expected SG&A [selling, general and administrative] costs.

Sales of key products, Truvada and Atripla, both exceeded expectations in the third quarter.  The Atripla uptake is going very well, and with the recent approval for Viread in HBV, Gilead remains well positioned to continue the strong top-line growth demonstrated over the past few years.   The pipeline is also progressing nicely.  Letairis should become the best-in-class ETRA for PAH, and given the lack of drug-drug interactions seen in the phase III trials, it should be used first-line with

...

We remain optimistic about growth of Gilead Sciences Inc.Â’s (GILD) HIV/AIDS franchise drugs Truvada and the recently approved Atripla. Earnings over the past few quarters have been above expectations specifically on strong sales of the HIV franchise products. We continue to be positive on the name and are looking for a strong remainder of 2008.We consider Truvada a reformulation of drugs Viread and Emtriva to be a potential breakthrough product for the treatment of HIV/AIDS. Additionally, the approval of Atripla offers the next big wave of topline growth for the company. We are currently at a Hold rating as we think the current price fairly represents the story. However, longer-term, we remain bullish as Gilead is a core biotech to own. Our target is $55 based on strong 2008 EPS growth, confidence in the long-term growth rate which now includes Myogen, and better penetration for ...

Gilead Sciences Inc. (GILD) is freezing prices on most AIDS/HIV drugs it sells to government drug-assistance programs, and limiting even patients with private insurance to payments of $50 per month.

In response to AIDS patient advocacy groups, the Foster City, CA developer and manufacturer of some of the best-selling treatments to suppress the AIDS virus said it will suspend price increases on its antiretroviral drugs to government payers through 2010.

The decision came in a letter from Gregg Alton, Gilead’s senior vice president and general counsel, to the AIDS Healthcare Foundation in Los Angeles.

Alton, who is also on the board of the foundation, cited concerns raised by the foundation, the Fair Pricing Coalition and other groups. The foundation in March asked nine drugmakers to freeze their prices due to state budget constraints.

Gilead charges state drug assistance programs $840 a month for its best-selling HIV drug Truvada, a pill that combines

...